Until very recently, the study of human disease involved looking at big things — like organs or macroscopic systems — and figuring out when and how they can stop working properly. But that’s all started to change: in recent decades, new techniques have allowed us to look at disease in a much more detailed way, by examining the behaviour and characteristics of single cells.

One class of those techniques now known as single-cell genomics — the study of gene expression and function at the level of single cells. Single-cell genomics is creating new, high-dimensional datasets consisting of tens of millions of cells whose gene expression profiles and other characteristics have been painstakingly measured. And these datasets are opening up exciting new opportunities for AI-powered drug discovery — opportunities that startups are now starting to tackle head-on.

Joining me for today’s episode is Tali Raveh, Senior Director of Computational Biology at Immunai, a startup that’s using single-cell level data to perform high resolution profiling of the immune system at industrial scale. Tali joined me to talk about what makes the immune system such an exciting frontier for modern medicine, and how single-cell data and AI might be poised to generate unprecedented breakthroughs in disease treatment on this episode of the TDS podcast.

---

Intro music:

➞ Artist: Ron Gelinas

➞ Track Title: Daybreak Chill Blend (original mix)

➞ Link to Track: https://youtu.be/d8Y2sKIgFWc

---

Chapters:

0:00 Intro

2:00 Tali’s background

4:00 Immune systems and modern medicine

14:40 Data collection technology

19:00 Exposing cells to different drugs

24:00 Labeled and unlabelled data

27:30 Dataset status

31:30 Recent algorithmic advances

36:00 Cancer and immunology

40:00 The next few years

41:30 Wrap-up

The Most Underrated Shots in Tennis | Mailbag